[Translation] A multi-center, randomized, double-blind, parallel, placebo-controlled clinical phase III study to evaluate the efficacy and safety of subcutaneous injection of JS005 injection in the treatment of adults with moderate to severe chronic plaque psoriasis
主要研究目的
评价JS005治疗成人中重度慢性斑块状银屑病受试者第12周时达到银屑病面积与严重程度指数较基线改善至少90%(PASI 90)和静态医师全面评估(sPGA)评分为0或1的受试者比例是否均优于安慰剂。
次要研究目的
评价JS005治疗成人中重度慢性斑块状银屑病受试者的其他疗效指标、安全性。
评价JS005治疗成人中重度慢性斑块状银屑病受试者的药代动力学特征和免疫原性。
[Translation] Main research purpose
To evaluate JS005 treatment of adults with moderate to severe chronic plaque psoriasis who achieved at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) and a Static Physician's Global Assessment (sPGA) score of 0 at Week 12 Whether or not a proportion of subjects of 1 is superior to placebo.
Secondary research purpose
To evaluate other efficacy indicators and safety of JS005 in the treatment of adult subjects with moderate to severe chronic plaque psoriasis.
To evaluate the pharmacokinetic characteristics and immunogenicity of JS005 in adult subjects with moderate to severe chronic plaque psoriasis.